INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2008

Glucosamine and/or chondroitin sulfate did not significantly reduce joint space width loss at 2 years in knee osteoarthritis compared to placebo.

In the GAIT trial, 572 patients with knee osteoarthritis were randomized to receive glucosamine (500 mg 3 times daily), chondroitin sulfate (400 mg 3 times daily), their combination, celecoxib (200 mg daily), or placebo over 24 months. Adjusted mean joint space width (JSW) loss at 2 years in the placebo group was 0.166 mm, and no statistically significant difference in mean JSW loss was seen in any treatment group compared with placebo. A trend toward improvement was observed in Kellgren/Lawrence grade 2 knees, but not grade 3 knees. The authors noted study power was diminished by limited sample size, variance of JSW measurement, and smaller than expected JSW loss.

Study type
24-month double-blind placebo-controlled randomized trial
Who was studied
572 patients with knee osteoarthritis and radiographic Kellgren/Lawrence grade 2 or 3 changes with baseline joint space width >= 2 mm
What was measured
Mean change in minimum medial tibiofemoral joint space width from baseline to 24 months

THE PAPER

The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trial.

Sawitzke AD, Shi H, Finco MF, Dunlop DD, Bingham CO, Harris CL, Singer NG, Bradley JD, Silver D, Jackson CG, Lane NE, Oddis CV, Wolfe F, Lisse J, Furst DE, Reda DJ, Moskowitz RW, Williams HJ, Clegg DO. Arthritis Rheum, 2008.

PubMed 18821708 ↗DOI 10.1002/art.23973 ↗

Bones & muscles

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.